Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Physician
Patient
Health Care Practitioner
Pharma / Biotech Industry
Other
Topics:
Endocrinology
•
Bone and Calcium Disorders
•
Primary Care
Do you recommend the use of Denosumab for osteoporosis management in patients receiving IVIG therapy?
Related Questions
How frequently do you monitor for hypocalcemia in patients on romosozumab?
What range of musculoskeletal complaints have you seen with romosozumab use?
Would you continue Forteo treatment past the recommended 2 years if T scores remain low and procollagen (P1NP) is elevated and if so, how would you monitor response?
How do you manage osteoporosis treatment following parathyroidectomy for primary hyperparathyroidism?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
How do you approach a patient with elevated bone specific ALP (>2X the normal limit), but no other evidence of Paget's disease?
Is there any role for 25-OH Vitamin D testing in patients older than 75 years old in the general population?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
What is your approach to managing symptomatic primary hyperparathyroidism in the third trimester of pregnancy?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
